The biopharmaceutical sector is one of the seven priority industries championed by China's 12th Five-Year Plan and changes are now being put into effect.
Though once predominantly focused on producing generics and performing contract research for Western companies, the Chinese biopharmaceutical industry is now developing at a rapid pace in China. This growth has been spurred by generous government investment and the resturn of thousands of China-born, Western-trained researchers and managers. Additionally, more Chinese companies are now engaging in new drug discovery and foreign pharmaceutical companies, large and small, are clamoring to set up partnerships with them. Read the full story.